Have to agree Pte.Parts.
Phase 2 monotherapy K9 trial with readout by Xmas.
Phase 1 (2016) results 6 of 7 (of memory) stable disease.
Issues on palatability resolved, potency increased on current formula (P2), just need a higher efficacy on this increased population (27 K9 participants of memory).
Low registry ( under 300mil shares), good management, and circa 30-35 MC.
Have a great weekend holders, hold tight, closer each day.
What is driving the price down, page-7
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.3¢ | 19.0¢ | $25.41K | 133.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5372 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 262575 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |